SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

KT, just a comment related to your post

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
JamesGMS Member Profile
 
Followed By 29
Posts 364
Boards Moderated 0
Alias Born 02/15/05
160x600 placeholder
Peregrine Announces Date of 2017 Annual Meeting of Stockholders "GlobeNewswire Inc." - 11/13/2017 8:05:00 AM
Ronin Trading and SW Investment Management Release Presentation Highlighting Concerns with Board of Peregrine Pharmaceuticals "PR Newswire (US)" - 10/30/2017 11:54:00 AM
Ronin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine Pharmaceuticals "PR Newswire (US)" - 10/27/2017 8:30:00 AM
Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices "GlobeNewswire Inc." - 10/24/2017 8:05:00 AM
Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices "GlobeNewswire Inc." - 10/19/2017 8:05:00 AM
Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals "PR Newswire (US)" - 10/10/2017 12:59:00 PM
CORRECTING and REPLACING Announcing VanEck Vectors Equity ETF’s September 2017 Distributions "Business Wire" - 10/2/2017 12:35:00 PM
Announcing VanEck Vectors Equity ETF’s September 2017 Distributions "Business Wire" - 9/29/2017 5:25:00 PM
Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Lit... "GlobeNewswire Inc." - 9/25/2017 8:05:00 AM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 9/19/2017 2:51:59 PM
Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition "GlobeNewswire Inc." - 9/19/2017 8:05:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/14/2017 5:21:37 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/14/2017 5:19:50 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 9/11/2017 5:14:45 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 5:04:28 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/11/2017 5:02:13 PM
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments "GlobeNewswire Inc." - 9/11/2017 4:05:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 3:37:19 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 9/11/2017 3:35:34 PM
Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices "GlobeNewswire Inc." - 9/11/2017 8:05:00 AM
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combinati... "GlobeNewswire Inc." - 9/7/2017 8:10:00 AM
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017 "GlobeNewswire Inc." - 9/6/2017 4:05:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/5/2017 4:31:30 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 9/5/2017 4:05:00 PM
JamesGMS   Monday, 07/17/17 07:31:27 PM
Re: keep_trying post# 304172
Post # of 318945 
KT, just a comment related to your post excerpted in relevant part below:

Quote:
Oops, the faction on Item T was for that Phase 2 study where the dose switching left PPHM retail shareholders "at the altar" after the run up to over $5 1/2 pps, pre split.

The Phase 3 trial halt was on its own path. There were at least three unusual trial results related events that left expectations for PPHM successful commercialization with a set back, by my recollection:

1. the unusual control group performance that showed the placebo group outperforming previous trial control groups by a large margin. . . . . . . . .



The Phase III result was particularly difficult as Garnick et al were highly confident of an approval - most likely after the second look, and, as reiterated to me once again by a close associate of Dr. Garnick just last week, Bavi did indeed perform exactly as expected - actually better than Opdivo in a very similar trial - which really made our result that much more difficult to understand. Dr. Garnick did his job - Bavi should have been approved last year.

Enjoy your evening.

James


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist